INS and cancer: Epidemiological, clinical and experimental reports support that metabolic syndrome associated with insulin confers an increased risk of developing various cancers, including breast, endometrial, ovarian, colon and prostate cancers, as well as diseases associated with insulin resistance syndrome such as type 2 diabetes (21).